Participant flow

Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support · Source last updated 2012-02-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Busulfan starting 0.8 mg/kg by vein (IV) every 6 hours for 12 doses; Fludarabine 30 mg/m\^2 IV daily for 4 days.

   id

   FG000

   title

   Busulfan + Fludarabine

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         80

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         80

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Of the 82 participants enrolled, two (2) participants were excluded from the trial before starting treatment.

recruitment Details

Recruitment period: November 2003 to August 2011. All recruitment was done at UT MD Anderson Cancer Center.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice